Personalisierte Medizin und Typ-2-Diabetes: Pharmakogenetische Aspekte bei der Therapie

Schlüsselwörter

Typ-2-Diabetes - Arzneimitteltherapie - Pharmakogenetik - personalisierte Medizin

Keywords

diabetes mellitus type 2 - drug therapy - pharmacogenetics - personalized medicine

• Literatur

• 1 Chen S, Zhou J, Xi M et al. Pharmacogenetic variation and metformin response. Curr Drug Metab 2013; 14: 1070-1082
• 2 Floegel A, Stefan N, Yu Z et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013; 62: 639-648
• 3 Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012; 30: 1117-1124
• 4 Kwak SH, Park KS. Genetics of type 2 diabetes and potential clinical implications. Arch Pharm Res 2013; 36: 167-177
• 5 Mannino GC, Sesti G. Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 2012; 16: 285-302
• 6 Morris AP, Voight BF, Teslovich TM et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-990
• 7 Sanghera DK, Blackett PR. Type 2 Diabetes Genetics: Beyond GWAS. J Diabetes Metab 2012; 3, pii: 6948
• 8 Schindler C, Barthel A, Fischer S et al. Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes. Internist 2012; 53: 478, 480-485, 487
• 9 Scott RA, Lagou V, Welch RP et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012; 44: 991-1005
• 10 Seeringer A, Parmar S, Fischer A et al. Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. Diabetes Obes Metab 2010; 12: 1106-1112
• 11 van Leeuwen N, Nijpels G, Becker ML. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes. Diabetologia 2012; 55: 1971-1977
• 12 van Leeuwen N, Swen JJ, Guchelaar HJ et al. The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clin Pharmacokinet 2013; 52: 833-854
• 13 Waldeyer R, Brinks R, Rathmann W et al. Projection of the burden of type 2 diabetes mellitus in Germany. Diabet Med 2013; 30: 999-1008
• 14 Wang-Sattler R, Yu Z, Herder C et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012; 8: 615
• 15 Zhou K, Bellenguez C, Spencer CC et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43: 117-120